Dr. Mandujano is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8501 Wade Blvd
Ste 1020
Frisco, TX 75034Phone+1 972-668-5864Fax+1 972-668-5825
Education & Training
Tulane UniversityFellowship, Pediatric Pulmonology, 1991 - 1994
Rutgers Health/Newark Beth Israel Medical CenterResidency, Pediatrics, 1988 - 1991
Universidad Nacional Autonoma de Honduras Class of 1986
Certifications & Licensure
TX State Medical License 1997 - 2026
FL State Medical License 1997 - 2025
LA State Medical License 1991 - 2025
OH State Medical License 2021 - 2025
NJ State Medical License 1991 - 1993- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Pulmonology
Publications & Presentations
PubMed
- 3 citationsLong-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.Roger H Kobayashi, Jiří Litzman, Isaac Melamed, J Fernando Mandujano, Ai Lan Kobayashi
Clinical and Experimental Immunology. 2022-12-15 - Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig]) in the treatment of patients with primary immu...Roger H Kobayashi, Sudhir Gupta, Isaac Melamed, J Fernando Mandujano, Ai Lan Kobayashi
Frontiers in Immunology. 2022-01-01 - 2 citationsEfficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.Elena E. Perez, Jacques Hébert, Anne K. Ellis, Oral Alpan, William R. Lumry
Frontiers in Immunology. 2021-07-08
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
